BioNTech veröffentlicht Daten aus Studie mit mRNA-basiertem FixVac-Melanom-Programm BNT111 in Nature
July 30, 2020 03:00 ET
|
BioNTech SE
Vorläufige Phase-1-Ergebnisse der Lipo-MERIT-Studie mit Daten von 89 Patienten zeigen vorteilhaftes Verträglichkeitsprofil für BNT111 in Patienten mit fortgeschrittenem malignem...
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
July 30, 2020 03:00 ET
|
BioNTech SE
Preliminary Phase 1 results from Lipo-MERIT trial with data from 89 patients highlight favorable tolerability profile of BNT111 in advanced melanoma patientsEfficacy analysis in a subset of 42...
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
July 15, 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
What to Wear to Protect Your Skin From the Sun; American Academy of Dermatology
June 30, 2020 14:30 ET
|
American Academy of Dermatology
ROSEMONT, Ill., June 30, 2020 (GLOBE NEWSWIRE) -- Skin cancer is the most common cancer in the U.S., and nearly 20 Americans die from melanoma, the deadliest form of skin cancer, every day. As more...
Survey: 60% of Americans Say They Have Gotten Sunburned So Badly Their Clothes Were Uncomfortable
May 18, 2020 11:30 ET
|
American Academy of Dermatology
ROSEMONT, Ill., May 18, 2020 (GLOBE NEWSWIRE) -- Memorial Day — long considered the unofficial start of summer in the U.S. — is quickly approaching, and dermatologists from the American Academy of...
Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma
April 21, 2020 07:30 ET
|
Idera Pharmaceuticals, Inc.
– Overall response rate of 22% –– Disease control rate of 71% –– Median overall survival of 21 months –– Key topline data from ILLUMINATE-301 expected in Q1 2021 – EXTON, Pa., April 21, 2020 ...
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
March 05, 2020 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its...
Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study
November 05, 2019 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in...
Media Advisory - Save Your Skin Launches Inaugural “Move For Melanoma” Challenge Benefiting Skin Cancer Patients Across Canada
August 30, 2019 01:10 ET
|
Save Your Skin Foundation
VANCOUVER, British Columbia, Aug. 30, 2019 (GLOBE NEWSWIRE) -- On Friday, September 13th Save Your Skin Foundation will officially launch the 2019 Move for Melanoma Challenge. The unique campaign...
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
August 02, 2019 11:44 ET
|
AB Science
Paris, August 2, 2019, 5.30pm AB Science announces new clinical results in oncology: Masitinib showed activity in metastatic melanoma bearingthe juxta-membrane mutation of c-Kit AB...